학술논문
Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study
Document Type
Academic Journal
Author
Source
Revista Espanola de Enfermadades Digestivas (REED). August, 2023, Vol. 115 Issue 8, p444, 6 p.
Subject
Language
English
ISSN
1130-0108
Abstract
Background and aims: response to the SARS-CoV-2 vaccine can be altered in patients with immune-mediated diseases, such as inflammatory bowel disease, and in patients under immunosuppressive treatment. The aims of this study were to evaluate the serologic response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease, to analyze the influence of immunosuppressive drugs on response, and to describe any adverse events in this population. Methods: this was a prospective study that included adult patients with inflammatory bowel disease. Baseline characteristics, concomitant treatments and previous COVID-19 symptoms were collected. Patients underwent serological testing before the first and after the second vaccine dose. Results: a total of 265 patients were consecutively included. Patients received one of the following vaccines: messenger RNA vaccines from Pfizer/BioNTech and Moderna; and adenovirus vaccines from AstraZeneca and Janssen. All adverse events were mild, and the most frequent was injection site pain in 141 (86%) patients. The seroconversion rate according to the treatment that patients were receiving was: 100% for those without treatment, 92.5% for patients treated with mesalazine, 90.3% for those receiving immunomodulators, 88.9% for patients with biological monotherapy and 92.5% for patients on combined treatment. The generation of antibodies according to the vaccine administered was: Pfizer 92.9%, Moderna 93.3%, AstraZeneca 98.4%, and Janssen 12.5%. Conclusion: the antibody response after vaccination against SARS-CoV-2 is high in patients with inflammatory bowel disease. However, patients treated with immunosuppressive or biologic drugs had a lower response. Adverse events were frequent, but not serious. Keywords: Inflammatory bowel disease. COVID-19. Vaccine. Immunosuppressive treatment. Serologic response. Seroconversion.
INTRODUCTION It is well known that the outbreak of pneumonia now known as COVID-19 is caused by a new member of the coronavirus family, SARS-CoV-2 (1). As of March 23, [...]
INTRODUCTION It is well known that the outbreak of pneumonia now known as COVID-19 is caused by a new member of the coronavirus family, SARS-CoV-2 (1). As of March 23, [...]